Latest from Weill Cornell Sandra & Edward Meyer Cancer Center

Scott T. Tagawa, MD, discusses the potential of sacituzumab govitecan in advanced urothelial cancers and reflects on progress made in prostate cancer.
Manish A. Shah, MD, discusses the results of the GAMMA-1 trial and challenges that remain for patients with gastric cancer.
Allyson J. Ocean, MD, discusses the potential impact of SM-88 in the treatment of patients with advanced pancreatic cancer and highlights a platform that patients can use to stay updated on the latest research in the field.
Pinkal Desai, MD, MPH, assistant professor of medicine at Weill Cornell Medical College and assistant attending physician at the NewYork-Presbyterian Hospital, discusses advances made in the treatment of patients with acute myeloid leukemia (AML).
Scott T. Tagawa, MD, MS, discusses the clinical significance of recent clinical trial data in patients with nonmetastatic prostate cancer.
The R2 regimen of lenalidomide (Revlimid) plus rituximab (Rituxan) reduced the risk of disease progression or death by 54% versus rituximab alone in patients with relapsed/refractory indolent non-Hodgkin lymphoma. 
 
Scott T. Tagawa, MD, discusses an emerging treatment modality for patients with progressive metastatic castration-resistant prostate cancer.
Scott T. Tagawa, MD, MS, Richard A. Stratton Associate Professor in Hematology and Oncology, associate professor of clinical medicine & urology at Weill Cornell Medicine, associate attending physician, NewYork-Presbyterian–Weill Cornell Medical Center, discusses radiotherapy in the treatment of patients with prostate cancer.
 
Publication Bottom Border
Border Publication
x